Murray Baron

List of Publications by Year
in descending order

177 papers	7,991 citations	41258 49 h-index	60497 81 g-index
177 all docs	177 docs citations	177 times ranked	7116 citing authors

#	Article	IF	Citations
1	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	6.3	505
2	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis and Rheumatism, 2001, 44, 1351-1358.	6.7	361
3	Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. Arthritis and Rheumatism, 1994, 37, 32-40.	6.7	325
4	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the Rheumatic Diseases, 2018, 77, 212-220.	0.5	236
5	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology, 2011, 50, 762-767.	0.9	188
6	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
7	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychological Medicine, 2020, 50, 1368-1380.	2.7	175
8	Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Science Translational Medicine, 2017, 9, .	5.8	155
9	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis and Rheumatology, 2017, 69, 1067-1077.	2.9	139
10	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, 2017, 76, 270-276.	0.5	132
11	Depression in patients with systemic sclerosis: A systematic review of the evidence. Arthritis and Rheumatism, 2007, 57, 1089-1097.	6.7	131
12	Healthâ€related quality of life in systemic sclerosis: A systematic review. Arthritis and Rheumatism, 2009, 61, 1112-1120.	6.7	129
13	The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review. Journal of Rheumatology, 2013, 40, 1545-1556.	1.0	127
14	Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. Rheumatology, 2010, 49, 789-796.	0.9	118
15	Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry. Arthritis Care and Research, 2011, 63, 142-149.	1.5	118
16	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care and Research, 2012, 64, 519-524.	1.5	117
17	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisisâ€"Results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism, 2014, 43, 666-672.	1.6	115
18	Malnutrition Is Common in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group Database. Journal of Rheumatology, 2009, 36, 2737-2743.	1.0	114

#	Article	IF	Citations
19	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R50.	1.6	110
20	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	2.9	110
21	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	0.8	104
22	ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nature Medicine, 2017, 23, 1405-1415.	15.2	99
23	Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the Blood Markers Hyaluronic Acid, Orosomucoid, and Keratan Sulfate. Arthritis and Rheumatism, 1990, 33, 790-799.	6.7	91
24	Clinical and Serologic Correlates of Antiâ€PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients. Arthritis and Rheumatology, 2014, 66, 1608-1615.	2.9	90
25	Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 59, 504-509.	6.7	86
26	Psychological health and wellâ€being in systemic sclerosis: State of the science and consensus research agenda. Arthritis Care and Research, 2010, 62, 1181-1189.	1.5	79
27	Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015, 41, 459-473.	0.8	78
28	Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 59, 438-443.	6.7	77
29	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.5	77
30	Cigarette smoking in patients with systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 230-238.	6.7	74
31	Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. Arthritis Care and Research, 2010, 62, 409-417.	1.5	69
32	Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis and Rheumatism, 2008, 59, 270-278.	6.7	68
33	The needs of patients with arthritis: The patient's perspective. Arthritis and Rheumatism, 1999, 12, 85-95.	6.7	67
34	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics, 2020, 89, 25-37.	4.0	67
35	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars in Arthritis and Rheumatism, 2016, 46, 344-349.	1.6	66
36	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology, 2014, 53, 1386-1394.	0.9	65

#	Article	IF	Citations
37	Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic Conditions. Journal of Rheumatology, 2009, 36, 768-772.	1.0	64
38	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. Journal of Rheumatology, 2014, 41, 2179-2185.	1.0	63
39	Office capillaroscopy in systemic sclerosis. Clinical Rheumatology, 2007, 26, 1268-1274.	1.0	62
40	The cost of systemic sclerosis. Arthritis and Rheumatism, 2009, 61, 119-123.	6.7	62
41	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.0	62
42	Work Disability in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 2481-2486.	1.0	61
43	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	1.6	60
44	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. Arthritis Care and Research, 2015, 67, 582-587.	1.5	60
45	Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. Journal of Rheumatology, 2005, 32, 1273-8.	1.0	60
46	Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: Evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. Arthritis and Rheumatism, 2009, 61, 966-973.	6.7	59
47	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. British Journal of Psychiatry, 2018, 212, 377-385.	1.7	53
48	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	0.9	53
49	Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 850-858.	1.0	52
50	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	2.4	52
51	Calcinosis is associated with digital ischaemia in systemic sclerosisâ€”a longitudinal study. Rheumatology, 2016, 55, 2148-2155.	0.9	52
52	Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology, 2012, 51, 2146-2154.	0.9	51
53	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	0.9	51
54	The development of systemic sclerosis classification criteria. Clinical Rheumatology, 2007, 26, 1401-1409.	1.0	48

#	Article	IF	Citations
55	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clinical Rheumatology, 2014, 33, 207-214.	1.0	48
56	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis and Rheumatism, 2008, 59, 279-284.	6.7	47
57	Registries in systemic sclerosis: a worldwide experience. Rheumatology, 2011, 50, 60-68.	0.9	45
58	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	1.0	45
59	Sociodemographic and Disease Correlates of Body Image Distress among Patients with Systemic Sclerosis. PLoS ONE, 2012, 7, e33281.	1.1	44
60	Association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care and Research, 2010, 62, 1489-1495.	1.5	43
61	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology, 2013, 52, 2056-2061.	0.9	43
62	Relationship Between Disease Characteristics and Orofacial Manifestations in Systemic Sclerosis: Canadian Systemic Sclerosis Oral Health Study III. Arthritis Care and Research, 2015, 67, 681-690.	1.5	42
63	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	2.9	41
64	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 120, 104-111.	0.2	40
65	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acroâ€Osteolysis in Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 366-373.	1.5	40
66	Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. Rheumatology, 2013, 52, 1715-1720.	0.9	39
67	Aseptic necrosis of the talus and calcaneal insufficiency fractures in a patient with pancreatitis, subcutaneous fat necrosis, and arthritis. Arthritis and Rheumatism, 1984, 27, 1309-1313.	6.7	38
68	Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Research and Therapy, 2014, 16, R130.	1.6	38
69	Time to diagnosis in systemic sclerosis: Is sex a factor?. Arthritis and Rheumatism, 2009, 61, 274-278.	6.7	35
70	Development and validation of the briefâ€satisfaction with appearance scale for systemic sclerosis. Arthritis Care and Research, 2010, 62, 1779-1786.	1.5	35
71	Defining primary systemic sclerosis heart involvement: A scoping literature review. Seminars in Arthritis and Rheumatism, 2019, 48, 874-887.	1.6	35
72	Utility of the Patient Health Questionnaireâ€9 to Assess Suicide Risk in Patients With Systemic Sclerosis. Arthritis Care and Research, 2013, 65, 753-758.	1.5	34

#	Article	IF	Citations
73	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology, 2019, 58, 636-644.	0.9	34
74	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Annals of the Rheumatic Diseases, 2019, 78, 807-816.	0.5	33
75	FRI0258â€…CUMULATIVE INCIDENCE, SURVIVAL AND PREDICTORS OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS SUBSETS: PAH IS NOT INCREASED IN LIMITED VS DIFFUSE PATIENTS BY ADJUSTED COMPETING RISK ANALYSIS. Annals of the Rheumatic Diseases, 2020, 79, 713-713.	0.5	33
76	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2307-2312.	1.0	32
77	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. Journal of Pain and Symptom Management, 2016, 52, 43-53.	0.6	32
78	Pancreatitis in systemic lupus erythematosus. Arthritis and Rheumatism, 1982, 25, 1006-1009.	6.7	31
79	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis and Rheumatism, 2009, 61, 1765-1770.	6.7	31
80	Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. Rheumatology, 2013, 52, 669-675.	0.9	31
81	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	1.5	31
82	Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 1925-1930.	1.0	29
83	Thinking outside the boxâ€”The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in Arthritis and Rheumatism, 2015, 45, 184-189.	1.6	29
84	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 2015, 48, 542-551.	1.2	29
85	67Gallium lung scans in progressive systemic sclerosis. Arthritis and Rheumatism, 1983, 26, 969-974.	6.7	28
86	Is Serum Albumin a Marker of Malnutrition in Chronic Disease? The Scleroderma Paradigm. Journal of the American College of Nutrition, 2010, 29, 144-151.	1.1	28
87	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 338-344.	1.6	28
88	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clinical and Experimental Rheumatology, 2012, 30, S23-9.	0.4	28
89	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 891-896.	1.6	26
90	Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 799-805.	1.0	25

#	Article	IF	Citations
91	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. Journal of Scleroderma and Related Disorders, 2017, 2, 42-49.	1.0	25
92	Methods for shortening patient-reported outcome measures. Statistical Methods in Medical Research, 2019, 28, 2992-3011.	0.7	25
93	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. Arthritis Care and Research, 2016, 68, 673-680.	1.5	24
94	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 2015, 33, S131-5.	0.4	24
95	Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. Rheumatology, 2011, 50, 921-925.	0.9	23
96	Rates and correlates of sexual activity and impairment among women with systemic sclerosis. Arthritis Care and Research, 2012, 64, 340-350.	1.5	23
97	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clinical and Experimental Rheumatology, 2010, 28, S42-6.	0.4	23
98	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. Journal of Rheumatology, 2014, 41, 1334-1343.	1.0	22
99	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	1.2	21
100	The Canadian Systemic Sclerosis Oral Health Study II: the relationship between oral and global health-related quality of life in systemic sclerosis. Rheumatology, 2015, 54, 692-696.	0.9	20
101	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. Autoimmunity Reviews, 2018, 17, 267-275.	2.5	19
102	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. Rheumatology, 2020, 59, 398-406.	0.9	19
103	Oxidative stress-induced senescence mediates inflammatory and fibrotic phenotypes in fibroblasts from systemic sclerosis patients. Rheumatology, 2022, 61, 1265-1275.	0.9	19
104	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	1.6	18
105	Toward Understanding of Environmental Risk Factors in Systemic Sclerosis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 188-204.	0.6	17
106	Sexual Activity and Impairment in Women with Systemic Sclerosis Compared to Women from a General Population Sample. PLoS ONE, 2012, 7, e52129.	1.1	17
107	Colonic telangiectasias in a patient with progressive systemic sclerosis. Arthritis and Rheumatism, 1986, 29, 282-285.	6.7	16
108	Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1226-1229.	1.0	16

#	Article	IF	Citations
109	Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. Journal of Rheumatology, 2013, 40, 447-454.	1.0	15
110	Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor. PLoS ONE, 2014, 9, e100035.	1.1	15
111	Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain. Journal of Rheumatology, 2011, 38, 2581-2587.	1.0	14
112	Systemic Sclerosis in Canadaâ€™s North American Native Population: Assessment of Clinical and Serological Manifestations. Journal of Rheumatology, 2013, 40, 1121-1126.	1.0	14
113	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, 1715-1724.	0.9	14
114	Does cigarette smoking mitigate the severity of skin disease in systemic sclerosis?. Rheumatology International, 2013, 33, 943-948.	1.5	13
115	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. PLoS ONE, 2014, 9, e91979.	1.1	13
116	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology, 2016, 56, kew441.	0.9	13
117	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	1.5	13
118	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology, 2018, 57, 152-157.	0.9	13
119	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.0	13
120	Modeling smoking in systemic sclerosis: A comparison of different statistical approaches. Arthritis Care and Research, 2011, 63, 570-578.	1.5	12
121	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physicianâ€™s Global Assessment of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 2016, 43, 1510-1518.	1.0	12
122	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology, 2020, 59, 1108-1117.	0.9	12
123	Can Patientâ€Reported Symptoms Be Used to Measure Disease Activity in Systemic Sclerosis?. Arthritis Care and Research, 2020, 72, 1459-1465.	1.5	12
124	Reasons for non-participation in scleroderma support groups. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 56-62.	0.4	12
125	Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1. BBA Clinical, 2014, 1, 2-11.	4.1	11
126	Subsets in systemic sclerosis: one size does not fit all. Journal of Scleroderma and Related Disorders, 2016, 1, 298-306.	1.0	11

#	Article	IF	Citations
127	Development and Validation of the Body Concealment Scale for Scleroderma. Arthritis Care and Research, 2016, 68, 1158-1165.	1.5	11
128	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. Rheumatology, 2017, 56, 1111-1122.	0.9	11
129	Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology, 2022, 61, 2905-2914.	0.9	11
130	Associations with Organ Involvement and Autoantibodies in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group (CSRG). Open Journal of Rheumatology and Autoimmune Diseases, 2013, 03, 113-118.	0.1	11
131	Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Medical Journal, 2016, 7, e0030.	0.4	11
132	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology, 2021, 39, 124-133.	0.4	11
133	Evaluation of the clinimetric properties of the Early Inflammatory Arthritis–self-administered comorbidity questionnaire. Rheumatology, 2009, 48, 390-394.	0.9	10
134	The challenges and controversies of measuring disease activity in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2018, 3, 115-121.	1.0	10
135	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Healthâ€Related Quality of Life. Arthritis and Rheumatology, 2021, 73, 305-314.	2.9	10
136	Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2022, 53, 151980.	1.6	10
137	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. Clinical Rheumatology, 2017, 36, 373-379.	1.0	9
138	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. PLoS ONE, 2014, 9, e102897.	1.1	9
139	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	1.5	8
140	Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. Journal of Scleroderma and Related Disorders, 2018, 3, 221-227.	1.0	8
141	Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. Clinical Rheumatology, 2013, 32, 1467-1474.	1.0	7
142	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	1.0	6
143	NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. Journal of Scleroderma and Related Disorders, 2022, 7, 62-70.	1.0	6
144	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 53-60.	0.4	6

#	Article	IF	Citations
145	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39, 142-148.	0.4	6
146	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 1156-1162.	1.0	5
147	Assessment of Englishâ€"French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. Body Image, 2017, 22, 97-102.	1.9	5
148	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). Arthritis Research and Therapy, 2020, 22, 132.	1.6	5
149	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. Chest, 2021, 160, 2158-2162.	0.4	5
150	Damage Trajectories in Systemic Sclerosis Using <scp>Groupâ€Based</scp> Trajectory Modeling. Arthritis Care and Research, 2023, 75, 640-647.	1.5	5
151	Development of the McGill Range of Motion Index. Clinical Orthopaedics and Related Research, 2007, 456, 42-50.	0.7	4
152	Immunosuppression for interstitial lung disease in systemic sclerosis â€" novel insights and opportunities for translational research. Journal of Cell Communication and Signaling, 2012, 6, 187-190.	1.8	4
153	Small intestinal bacterial overgrowth in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 33-39.	1.0	4
154	Immunosuppression use in early systemic sclerosis may be increasing over time. Journal of Scleroderma and Related Disorders, 2022, 7, 33-41.	1.0	4
155	Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management. Diagnostics, 2021, 11, 1781.	1.3	4
156	Anti-HMGCR antibodies in systemic sclerosis. Medicine (United States), 2016, 95, e5280.	0.4	4
157	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures. Seminars in Arthritis and Rheumatism, 2022, 53, 151973.	1.6	4
158	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	1.0	3
159	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	1.9	3
160	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. Rheumatology, 2022, 61, 3401-3407.	0.9	3
161	Novel Approaches to Discovery of Biomarkers in Rheumatoid Arthritis: Comment on the Article by Oswald et al. Arthritis and Rheumatology, 2015, 67, 2276-2277.	2.9	2
162	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 57-63.	1.0	2

#	Article	IF	Citations
163	Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis. Journal of Scleroderma and Related Disorders, 2020, 5, 152-158.	1.0	2
164	Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group. Journal of the American Academy of Dermatology, 2022, 87, 1095-1097.	0.6	2
165	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 56-60.	0.4	2
166	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply. Rheumatology, 2020, 59, 1783-1784.	0.9	1
167	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. Respiratory Medicine, 2021, 185, 106482.	1.3	1
168	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, 44, 1351.		1
169	Hepatic Overlap Syndrome Improved With Infliximab. Gastroenterology and Hepatology, 2006, 2, 88-90.	0.2	1
170	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 124-133.	0.4	1
171	Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers. Arthritis Care and Research, 2022, , .	1.5	1
172	Patient-reported outcome measures in systemic sclerosis: Comment on the article by Hinchcliff et al. Arthritis Care and Research, 2012, 64, 942-943.	1.5	0
173	Reply. Arthritis Care and Research, 2014, 66, 497-498.	1.5	0
174	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	0.9	0
175	Trigeminal neuralgia in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2021, 51, 318-323.	1.6	0
176	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 142-148.	0.4	0
177	Effect of pregnancy on scleroderma progression. Journal of Scleroderma and Related Disorders, 0, , 239719832211013.	1.0	0